Onkologie 2020: 14(Suppl.D): 92-97 | DOI: 10.36290/xon.2020.048

Treatment of a patient with differentiated thyroid carcinoma - a case report.

Hana Švébišová1, Kamil Bukovanský2
1 Onkologická klinika, Fakultní nemocnice Olomouc
2 Klinika nukleární medicíny, Fakultní nemocnice Ostrava

Patients with radio-refractory differentiated thyroid carcinoma (RR-DTC) are indicated for therapy with tyrosine kinase inhibitors (TKI). In the Czech Republic, treatment is concentrated to Complex Oncology Centers. Patients are mostly middle age and older, with comorbidities.The case report describes the case of a patient who, despite the advancement of cancer, significant co-morbidity and the distance of her residence from our healthcare facility, benefits from cancer treatment.

Keywords: radioiodine refractory differentiated thyroid carcinoma, TKI, comorbidity, benefit from cancer treatment.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Švébišová H, Bukovanský K. Treatment of a patient with differentiated thyroid carcinoma - a case report. Onkologie. 2020;14(Suppl.D / Onkologické kazuistiky 3):92-97. doi: 10.36290/xon.2020.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brose MS, Nutting CM, Jarzab B, et al. On behalf of the DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384(9940): 319-328. Go to original source... Go to PubMed...
    2. Schulmberger M, Makoto Tahara, Wirth Lori J, et al. Lenvatinib versus Placebo in radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015; 372: 621-630. Go to original source... Go to PubMed...
    3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology [online], 2016, http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf>
    4. Modrá kniha České onkologické společnosti, www.linkos.cz
    5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428. Go to original source... Go to PubMed...
    6. Vlček P. Diferencovaný karcinom štítné žlázy - nový pohled na jeho léčbu. Onkologie 2011: 5(6): 329-332.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.